Preserving Nipple Sensitivity after Breast Cancer Surgery: A Systematic Review and Meta-Analysis

Table 2

Patient demographics, disease characteristics, and surgical complications by study.

Study

Patient characteristics

Disease characteristics and treatment

Complications

Average age

SD

Average BMI (kg/m^2)

SD

Breast cancer type

Chemotherapy

Radiation

Reconstruction

Neurotization of NAC

NAC necrosis

Dehiscence

Unplanned reoperation

Benediktsson et al.

54

40–80 (range)

Not provided

Not provided

Not provided

19 (24%)

17 (21%)

Nonautologous = 80 (100%)

0 (0%)

Not provided

Not provided

Not provided

Chirappapha et al.

43

30–60 (range)

23.1

16.3–43.8 (range)

Invasive carcinoma = 33 (77%); DCIS = 10 (23%); Benign phyllodes tumor = 3 (6%); Benign condition = 8 (15%)

Not provided

Not provided

Both autologous and nonautologous (numbers not specified)

0 (0%)

11 (20%)

Not provided

3 (5.5%)

Djohan et al.

46.5

9.42

24

4.79

Prophylactic = 12 (15.4%); DCIS (29, 37.2%); LCIS (3, 3.8%); Infiltrating (34, 43.5%)

Not provided

Not provided

Nonautologous, n = 84 (72.4%); Autologous, n = 32 (27.6%)

0 (0%)

2 (2.6%)

Not provided

31 (39.7%)

Djohan et al.

38.12

7.5

23.66 (4.19)

4.19

Not provided

4 (26.8%)

0 (0%)

Nonautologous, n = 15 (100%)

15 (100%)

2 (13.4%)

1 (6.7%)

Not provided

Eichler et al.

52.9

9.3

Not provided

Not provided

DCIS (14, 9.8%); IDC (104, 72.8%); ILC (18, 12.6%); Others (6, 4.2%)

94 (65.8%)

Not provided

Not provided

0 (0%)

Not provided

Not provided

Not provided

Franceschini et al.

45.3

27–73 (range)

24.4

17.5–29.4 (range)

Not provided

73 (41.2%)

45 (25.4%)

Nonautologous = 177 (100%)

0 (0%)

1 (1.2%)

Not provided

Not provided

Gahm et al.

39 (median)

26–58 (range)

Not provided

Not provided

Prophylactic = 46 (100%)

0

Not provided

Nonautologous = 46 (100%)

0 (0%)

Not provided

Not provided

Not provided

Glaumann et al.

Not provided

Not provided

Not provided

Not provided

Not provided

Not provided

Not provided

Autologous = 7, 9.7%; Nonautologous = 62, 86.1%

0 (0%)

4 (3.4%)

Not provided

41 (35.0%)

Khan et al.

51 (median)

30–72 (range)

Not provided

Not provided

Not provided

Not provided

Not provided

Autologous = 4 (2.2%); Nonautologous = 73 (40.3%); Both = 68 (37.6%)

0 (0%)

Not provided

Not provided

Not provided

Kim et al.

44.5

7.53

21.3

2.52

Not provided

64 (45.7%)

Not provided

Nonautologous = 140 (100%)

0 (0%)

Not provided

Not provided

5 (3.6%)

Manie et al.

50

41–66 (range)

36.7

31.6–44.9 (range)

Not provided

5 (35.7%)

Not provided

Not provided

0 (0%)

0 (0%)

1 (7%)

1 (7%)

Nahabedian et al.

48.8

35–72 (range)

Not provided

Not provided

Not provided

Not provided

Not provided

Nonautologous = 8 (57.1%); Autologous = 6 (42.8%)

0 (0%)

1 (7.1%)

Not provided

5 (35.7%)

Ou et al.

45.2

29–67 (range)

21.8

17.48–27.15 (range)

DCIS (12, 27.3%); LCIS (1, 2.3%); IDC (29, 65.9%); ILC (1, 2.3%); Phyllodes (1, 2.3%)

21 (47.7%)

7 (15.9%)

Nonautologous = 38 (86.4%); Autologous = 6 (13.6%)

0 (0%)

6 (13.6%)

Not provided

4 (9.1%)

Pan et al.

41 (median)

35–45 (IQR)

Not provided

Not provided

IDC (27, 65.9%)

0 (0%)

45 (100%)

Nonautologous = 41 (100%)

0 (0%)

3 (7.3%)

Not provided

Not provided

Pek et al.

47

8.8

23.5

4.5

Not provided

Not provided

0 (0%)

Autologous = 148 (84.6%); Nonautologous = 27 (15.4%)

0 (0%)

17 (12.0%)

Not provided

8 (5.6%)

Peled et al.

47.8

30.4–69.9 (range)

23.2

17.3–27.7 (range)

Not provided

14 (50%)

4 (14.3%)

Nonautologous = 46 (100%)

0 (0%)

3 (10.7%)

Not provided

3 (10.7%)

Peled et al.

Not provided

Not provided

Not provided

Not provided

Not provided

Not provided

Not provided

Nonautologous = 31 (100%)

31 (100%)

Not provided

Not provided

Not provided

Petit et al.

46

20–73 (range)

Not provided

Not provided

Invasive carcinoma (819, 82%); IDC (182, 18.2%)

Not provided

1001 (100%)

Nonautologous = 991 (99%); Autologous = 10 (1%)

0 (0%)

80 (8.0%)

Not provided

93 (9.3%)

Rodriguez-Unda et al.

50.2

8.6

25.6

4.1

Not provided

35 (79.5%)

16 (36.4%)

Nonautologous = 37 (50%); Autologous = 37 (50%)

0 (0%)

Not provided

Not provided

108 (245%)

Shaffer et al.

48

29–63 (range)

Not provided

Not provided

Atypia/DCIS (2, 5%); Invasive cancer (20, 50%)

12 (30%)

3, 7.5%

Nonautologous = 74 (100%)

0 (0%)

0 (0%)

Not provided

Not provided

Stanec et al.

46.6

9

Not provided

Not provided

IDC (212, 50.4%); ILC (71, 16.9%); DCIS (63, 15%); Others (28, 6.5%)

Not provided

Not provided

Autologous (276, 65.6%); Nonautologous (145, 34.4%)

0 (0%)

29 (10.1%)

Not provided

Not provided

Tevlin et al.

49

10.4

28.7

4.8

Not provided

Not provided

0, 0%

Autologous (14, 100%)

14 (100%)

Not provided

Not provided

Not provided

Tomita et al.

46

26–66 (range)

Not provided

Not provided

Not provided

32 (30.8%)

70 (67.3%)

Autologous = 104 (100%)

0 (0%)

Not provided

Not provided

Not provided

van Verschuer et al.

40 (median)

26–71 (range)

Not provided

Not provided

Not provided

5 (11.1%)

2 (4.4%)

Nonautologous = 45 (100%)

0 (0%)

7 (15.6%)

Not provided

17 (37.8%)

Wang et al.

44.22

8.56

Not provided

Not provided

Not provided

54 (83.3%)

27 (45.0%)

Autologous = 19 (31.7%); Nonautologous = 37 (61.7%); None = 4 (6.6%)

0 (0%)

Not provided

Not provided

Not provided

Yueh et al.

44

25–57 (range)

Not provided

Not provided

Benign breast disease (3, 17.6%); LCIS (2, 11.8%); DCIS (1, 5.9%); Invasive carcinoma (1, 5.9%)

Not provided

Not provided

Nonautologous = 15 (88.3%); Autologous = 2 (11.7%)

0 (0%)

3 (17.6%)

Not provided

7 (41.1%)

Data reported as a range. Data reported as a median and/or interquartile range (IQR). Includes delayed reconstruction (22%). All other studies include only immediate reconstruction. DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IQR, interquartile range; LCIS, lobular carcinoma in situ; NAC, nipple-areola complex; SD, standard deviation.